Background

Cancer progression relies on evasion of the immune response. Immune checkpoint blockade (ICB) therapy restores this immune response for many cancer types by preventing the binding of immune checkpoints on the surface of immune cells to their ligands. Resistance to ICB therapy is common, therefore monitoring the response to ICB treatment is essential for improving cancer treatment.

Technology Overview

Researchers at McMaster University have discovered novel multigene and individual gene panels that can effectively predict response to ICB therapy.

Further details:

1. Li, X., Shao, C., Shi, Y. et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol 11, 31 (2018). https://doi.org/10.1186/s13045-018-0578-4
2. Gu, Y., Lin, X., Dong, Y. et al. PCSK9 facilitates